Data completeness
1/8 — Limited
CLISTIN (carbinoxamine maleate) by Johnson & Johnson is mechanism of actions carbinoxamine maleate, an ethanolamine derivative, is an antihistamine with anticholinergic (drying) and sedative properties.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLISTIN (carbinoxamine maleate) is an oral tablet antihistamine belonging to the ethanolamine derivative class with anticholinergic and sedative properties. It competitively blocks H1 histamine receptors on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The product is currently in pre-launch stage under Johnson & Johnson sponsorship.
Pre-Launch
Pre-launch stage suggests team expansion in commercial planning, market access, and field readiness; hiring activity likely concentrated in launch preparation roles.
Mechanism of Action
Mechanism of Actions Carbinoxamine maleate, an ethanolamine derivative, is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CLISTIN offers early-stage career exposure in product launch strategy, market positioning, and pre-commercial planning within a major pharmaceutical organization. This pre-launch window presents opportunities to shape brand narrative, competitive strategy, and go-to-market execution from inception.
Brand Manager
Worked on CLISTIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.